MX2020002683A - Composiciones topicas y metodos de tratamiento. - Google Patents

Composiciones topicas y metodos de tratamiento.

Info

Publication number
MX2020002683A
MX2020002683A MX2020002683A MX2020002683A MX2020002683A MX 2020002683 A MX2020002683 A MX 2020002683A MX 2020002683 A MX2020002683 A MX 2020002683A MX 2020002683 A MX2020002683 A MX 2020002683A MX 2020002683 A MX2020002683 A MX 2020002683A
Authority
MX
Mexico
Prior art keywords
methods
topical compositions
treatment
endoxifen
hormone
Prior art date
Application number
MX2020002683A
Other languages
English (en)
Inventor
Steven C Quay
Avadhesh S Kushwaha
Edward T Kisak
John M Newsam
Original Assignee
Atossa Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atossa Therapeutics Inc filed Critical Atossa Therapeutics Inc
Publication of MX2020002683A publication Critical patent/MX2020002683A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción proporciona composiciones tópicas novedosas que comprenden endoxifeno y sales y solvatos del mismo y métodos para elaborar las composiciones; ciertos compuestos han sido combinados para formar composiciones tópicas estables que comprenden endoxifeno; la presente descripción también proporciona métodos para el tratamiento de trastornos de mama dependientes de hormonas y del tracto reproductivo dependientes de hormonas.
MX2020002683A 2017-09-11 2018-09-10 Composiciones topicas y metodos de tratamiento. MX2020002683A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762556920P 2017-09-11 2017-09-11
US201762556884P 2017-09-11 2017-09-11
US201762556799P 2017-09-11 2017-09-11
US201862624787P 2018-01-31 2018-01-31
US201862693885P 2018-07-03 2018-07-03
PCT/US2018/050197 WO2019051370A1 (en) 2017-09-11 2018-09-10 TOPICAL COMPOSITIONS AND METHODS OF TREATMENT

Publications (1)

Publication Number Publication Date
MX2020002683A true MX2020002683A (es) 2020-09-25

Family

ID=65634433

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002683A MX2020002683A (es) 2017-09-11 2018-09-10 Composiciones topicas y metodos de tratamiento.

Country Status (12)

Country Link
US (2) US20200215006A1 (es)
EP (1) EP3681478A4 (es)
JP (1) JP7376105B2 (es)
KR (1) KR20200051689A (es)
CN (1) CN111212631A (es)
AU (1) AU2018329182A1 (es)
CA (1) CA3074302A1 (es)
IL (1) IL272945A (es)
MX (1) MX2020002683A (es)
SG (1) SG11202001885WA (es)
TW (1) TW201919594A (es)
WO (1) WO2019051370A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL272924B2 (en) 2017-09-11 2024-01-01 Atossa Therapeutics Inc Methods for preparing and using endoxifen

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004251731A1 (en) * 2003-06-23 2005-01-06 Macrochem Corporation Compositons and methods for topical administration
US20070269379A1 (en) * 2003-07-23 2007-11-22 Samir Mitragotri Penetration Enhancer Combinations for Transdermal Delivery
CN102225046A (zh) * 2005-08-05 2011-10-26 努沃研究公司 透皮释药剂型
US20120164075A1 (en) * 2006-11-21 2012-06-28 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of mammalian diseases
JP2010510327A (ja) * 2006-11-21 2010-04-02 ジャイナ ファーマシューティカルズ，インコーポレーテッド エンドキシフェンの方法および組成物
CA2823407C (en) * 2007-03-22 2016-10-18 Berg Pharma Llc Topical formulations having enhanced bioavailability
EP3202420B1 (en) * 2008-12-11 2020-03-04 Besins Healthcare Luxembourg SARL Transdermal pharmaceutical compositions comprising a serm
US20100317635A1 (en) * 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
WO2014012117A1 (en) * 2012-07-13 2014-01-16 South Dakota State University Compositions and methods for localized drug delivery through mammary papillae
AU2016247674A1 (en) * 2015-04-14 2017-10-19 Atossa Genetics Inc. Compositions and methods of treatment of breast disorders and estrogen-related disorders

Also Published As

Publication number Publication date
TW201919594A (zh) 2019-06-01
JP7376105B2 (ja) 2023-11-08
CA3074302A1 (en) 2019-03-14
EP3681478A1 (en) 2020-07-22
CN111212631A (zh) 2020-05-29
US20200215006A1 (en) 2020-07-09
IL272945A (en) 2020-04-30
SG11202001885WA (en) 2020-03-30
US20240148675A1 (en) 2024-05-09
KR20200051689A (ko) 2020-05-13
JP2020533342A (ja) 2020-11-19
AU2018329182A1 (en) 2020-03-19
WO2019051370A1 (en) 2019-03-14
EP3681478A4 (en) 2021-07-14

Similar Documents

Publication Publication Date Title
MX2020009347A (es) Picolinamidas como fungicidas.
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
PH12018500177A1 (en) Compositions useful for treating disorders related to kit and pdfgr
PH12018501226A1 (en) Methods for treating huntingtons disease
PH12020500655A1 (en) Compounds
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2019015744A (es) Composiciones farmaceuticas.
MX2016017030A (es) Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos.
PH12015502414A1 (en) Enhancer of zeste homolog 2 inhibitors
NZ737399A (en) Ccr2 modulators
GEP20196949B (en) 2-amino-6-(difluoromethyl)-5, 5-difluoro-6-phenyl-3, 4, 5, 6-tetra- hydropyridines as bace1 inhibitors
MX2020002649A (es) Metodos para hacer y usar endoxifeno.
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
GEP20207108B (en) Substituted 2,4 diamino-quinoline as new anticancer agents
PH12017500737B1 (en) Kcnq2-5 channel activator
PH12020550703A1 (en) Sulfonamide compounds and use thereof
MX2016008150A (es) Formulaciones de berberina y usos de las mismas.
MX2020006434A (es) Nuevos compuestos inhibidores del blanco mecanistico de rapamicina (mtor).
PH12020550871A1 (en) Process for the preparation of opicapone and intermediates thereof
IN2013MU03862A (es)
MX2015008733A (es) Derivados de 1,2,3-triazol-4-amina para el tratamiento de enfermedades y transtornos relacionados con receptores sigma.
MX2019011613A (es) Formulaciones de acido 1-amino-1-ciclopropanocarboxilico.
PH12019502694A1 (en) Anti-trkb antibodies
GEP20186893B (en) Pyrazines modulators of gpr6
MX2021007687A (es) Sales novedosas de degradadores selectivos de receptores de estrogeno.